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Abstract: The occurrence of atherosclerosis and diabetes is expanding rapidly worldwide. These
two metabolic disorders often co-occur, and are part of what is often referred to as the metabolic
syndrome. In order to determine future therapies, we propose that molecular mechanisms should be
investigated. Once the aetiology of the metabolic syndrome is clear, a nutritional intervention should
be assessed. Here we focus on the protective effects of some dietary flavonoids, and their metabolites.
Further studies may also pave the way for development of novel drug candidates.
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1. Atherosclerosis
Atherosclerosis is known to predispose patients to myocardial infarction and stroke, and it is
responsible for cardiovascular ailments that represent the main cause of death in industrialised societies.
Disorders related to atherosclerosis, e.g., vascular inflammation and metabolic alterations, strongly
favour the onset and progression of a range of chronic diseases. The onset of these pathological events
is linked to several factors such as age, hypertension, diabetes mellitus, smoking, and dyslipidemia.
Atherosclerosis is a chronic, inflammatory, fibro-proliferative disorder, primarily of the large- and
medium-sized conduit arteries. The vascular production of reactive oxygen species (ROS), such as
O2−, derived from NADPH oxidase (NOX)-catalysed oxidations, represents a key event on the
road to endothelial dysfunction [1,2]. In fact, O2− and H2O2 stimulate vascular smooth muscle cell
(VSMC) hyperplasia and hypertrophy occurring along with intracellular alkalinization, increase of the
intracellular free calcium concentration, activation of MAP kinase, and induction of proto-oncogene
expression [3–6].
Endogenous and exogenous oxidants continuously trigger ROS generation in the vascular tissue
which results in atherosclerosis, neointimal hyperplasia, and hypertension [7–9]. Different authors have
reported that Angiotensin II-induced hypertension is, at least in part, due to oxidative stress [10,11].
Several natural extracts, e.g., from leaves of Olea europea L., or calyces of Hibiscus sabdariffa L. [12],
exert multiple effects that result in an inhibition of atherosclerosis and hypertension. The effects
include vasorelaxant, antioxidant and antinflammatory activities. Also, vegetal extracts rich in
hydrolyzable tannins, such as Castanea sativa Mill. bark [13] and Punica granatum L. extracts [14]
exert anti-atherogenic effects through several mechanisms including the suppression of inflammation
and oxidative stress, the inhibition of adhesion molecules such as VCAM-1 and ICAM-1, and the
lipid-lowering properties [15]. In addition, diets rich in flavonoids are consistently linked with
beneficial effects in the primary prevention of cardiovascular events.
Diseases 2017, 5, 19; doi:10.3390/diseases5030019 www.mdpi.com/journal/diseases
Diseases 2017, 5, 19 2 of 19
The main aim of this perspective is to critically explore flavonoids (Figure 1a: Structures of the
flavonoids discussed from this perspective; Figure 1b: Structures of the isoflavones discussed from this
perspective) and their antioxidant activities, and their ability to affect lipid levels and the development
of plaque, atherosclerosis, and its progression.
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2.2. Indirect Antioxidant Effects of Flavonoids: The Involvment of ET-1 and NADPH Oxidase
Several experimental models of hypertension, atherosclerosis and diabetes are characterised by
elevated levels of circulating ET-1 (Endothelin-1) [16–19].
ET-1 activates ETA/ETB receptors, leading to an augmented ROS production in vasculature,
which results in endothelial dysfunction [20–22].
NADPH oxidase represents the principal source of intracellular ROS in vascular cells. It is
a multi-subunit enzymatic complex that comprises two membrane-bound subunits named Nox
(Nox-1, Nox-2 or gp91phox, Nox-4 or Nox-5) and p22phox, whose regulation occurs through
cytoplasmic subunits like p47phox, p67phox and a low-molecular-weight G protein (rac 1 or rac 2) [23].
The signalling processes mediated by angiotensin II are multiphasic and occur at different times [24].
Following angiotensin II stimulation, activation of phospholipase C takes place within seconds
and then catalyses an increase of free intracellular calcium resulting in vascular contraction, while the
activation of signaling pathways which regulate protein synthesis and cell growth are delayed,
and occur only after minutes or hours after angiotensin II stimulation [24,25]. Different experimental
data suggest a direct correlation between angiotensin II stimulation and ROS generation, such as
O2−, OH and H2O2 [26–28]. The ROS production caused by angiotensin II can be divided into an
acute phase which comprises protein kinase C (PKC), c-Src, growth factor receptors transactivation
and translocation of cytosolic p47phox to the membrane [29,30], and a sustained phase, in which the
up-regulation of NADPH oxidase subunits (also involving PKC activation) occurs [31–33]. Interestingly,
in several animal models of hypertension, long term administration of quercetin has been shown to
restore the altered endothelial function [34]. This biological action may be due to the ability of quercetin
to decrease the production of vascular O2−, occurring mainly through two mechanisms: (1) direct
scavenging of O2− and inhibition of O2− generating enzyme [35]; (2) prevention of the expression of the
genes involved in O2− production, like NADPH oxidase subunits which can be induced by stimuli like
angiotensin II [36] or endothelin-1 (ET-1) [37]. Three quercetin metabolites, i.e., quercetin-3-glucuronide,
isorhamnetin-3-glucuronide and quercetin-3’-sulfate have been shown to prevent the impairment
of endothelial-derived NO response while only quercetin and quercetin-3-glucuronide are able to
prevent the in vitro ET-1 induced endothelial dysfunction. In particular, quercetin and its conjugated
metabolites (though with a lower potency) are able to partially prevent the DECTA-induced alteration
of contractile response of endothelium to Ach. Another activity of quercetin and its metabolites
contributing to improve endothelial dysfunction, is the concentration-dependent inhibition of the
production of O2− dependent on NADPH-oxidase [38]. This effect may be due to the ability
of quercetin and its metabolite isorhamnetin to inhibit protein kinase C (PKC). This enzyme is
activated by ET-1 and is in turn involved in Nox activation. Furthermore, these flavonols also reduce
ET-1-induced overexpression of p47phox, and thus provides further vascular protection. [39]. Also
quercetin-3′-sulfate and quercetin-3-glucuronide (100 micromol/L) inhibit NADPH oxidase-derived.
O2− release [38] Given orally to spontaneously hypertensive rats, quercetin reduces the aortic
expression of p47phox, and has not been detected in rats’ plasma, suggesting that the effect is
mediated by quercetin metabolites [38]. These data are in agreement with in vivo experiments
that have shown that long term treatment with quercetin reduces blood pressure and endothelial
dysfunction in different experimental models for hypertension [39–42]. Other flavonoids able to
inhibit NADPH oxidase are (−)-epicatechin [43–46], and its metabolites 3′-O-methyl-epicatechin,
4′-O-methyl epicatechin, epicatechin glucuronide (in particular the 3′ isomer, which is the main
metabolite in human plasma) [47], and procyanidin B2 [48,49]. SAR studies have pointed out the
fact that mono-O-methylation of catechol-type polyphenols change the biological activity from O2−
scavengers to exclusive NADPH oxidase inhibitors. In addition, the presence of a hydroxyl group in 4′
position of B-ring of flavonoids is an important feature for the inhibitory activity of flavonoids which
is found in 3′-O-methylated (−)-epicatechin, (+)-catechin, quercetin, fisetin, luteolin, kaempferol,
dihydrokaempferol, naringenin, able to exert this biological activity [50]. As regards the in vivo
activity, the fact that the (−)-epicatechin action is significantly inhibited by low concentrations of
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3,5-dinitrocatechol (DNC), an inhibitor of catechol-O-methyltransferase (COMT), suggests that the
O-methylation of (−)-epicatechin is essential. Conversion of epicatechin to 3′ and 4′-methyl ethers was
observed in vascular endothelial cells, and 3′-O-methyl epicatechin has been found in human plasma
after oral intake. In vascular endothelial cells, epicatechin determines an increase of the steady-state
level of nitric oxide, which is influenced by DNC. In contrast, the effect of the 3′-O-methyl epicatechin is
not affected by DNC. The NO− promoting action occurs through the inhibition of Nox, thus avoiding
the O2− generation. These observations made in mammalian cell cultures are in agreement with
the outcome of different clinical studies which demonstrated that intake of high-flavanol cocoa or
isolated epicatechin determines a transient improvement of endothelial function through elevated
bioavailability of NO− [50].
2.3. Indirect Antioxidant Effects of Flavonoids: The Involvement of Myeloperoxidase (MPO) and
HOCl Scavange
Another pathway leading to an increase of oxidative stress is directed by myeloperoxidase
(MPO), a secreted heme protein expressed at high levels in human atherosclerotic lesions, where it
co-localizes in part with macrophages, which use hydrogen peroxide (H2O2) to execute oxidative
reactions in the phagolysosome and extracellular milieu. This represents an important source of
oxidative stress in the human artery wall [51]. The main end product of this pathway is HOCl,
a strong chlorinating oxidant, able to chlorinate many different biomolecules, such as proteins, lipids,
and nucleic acids at the site of inflammation [51–53]. In addition, HOCl oxidizes LDL and high-density
lipoprotein in human arteries, resulting in the formation of atherogenic modified lipoproteins [51,54].
Some authors have suggested that the antiatherogenic effect of flavonoids may be due to MPO
inhibition. In particular, quercetin and its metabolite quercetin-3-glucuronide have been shown to
inhibit MPO in a concentration-dependent manner. In addition, plasma of quercetin-fed rats inhibits
MPO, suggesting the possibility that quercetin and its metabolites may inhibit the MPO-derived
oxidation reactions in vivo. Other flavonoids that inhibit MPO are, in order of potency, quercetin
> kaempferol > fisetin > luteolin > taxifolin. QSAR analysis suggest that OH groups in 3, 4′,
and 5 positions and C2-C3 double bond are necessary for MPO inhibition [55]. Apart from inhibiting
MPO, several flavonoids directly scavenge HOCl, forming the chlorinated flavonoid derivatives.
For example, quercetin, in presence of HOCl, is transformed into 6-mono and 6,8-dichlorinated
derivatives [56].
In animal experimental models, tea and tea-derived flavonoids, red wine-derived flavonoids,
and isolated quercetin or catechin, significantly inhibit atherosclerotic lesion development in the apo E
deficient mouse [56]. Similar results have been obtained with red grape extracts using cholesterol-fed
hamsters [57]. Using high cholesterol-fed rabbits, the antiatherogenic effects of the citrus flavonoids,
naringin and naringenin have been demonstrated. These effects are mediated, at least in part,
by the inhibition of hepatic acyl CoA: cholesterol acyltransferase (ACAT) activity, the decreased
cholesterol absorption and expression of VCAM-1 (vascular cell adhesion molecule-1) and MCP-1
(monocyte chemoattractant protein-1) which play important roles in the adhesion of monocytes to
the endothelium [58]. In addition, naringin has been shown to lower hypercholesterolemia-induced
intercellular adhesion molecule-1 (ICAM-1) expression on endothelial cells of hypercholesterolemic
rabbits [59]. Furthermore, quercetin, which is present in green and black tea, and the black tea flavonoid
theaflavin, inhibit the development of atherosclerosis in apo E deficient mice [60,61].
2.4. Flavonoids and Atherosclerosis: Clinical Studies
Daily administration of 100 mg of (−)-epicatechin and of 160 mg of quercetin-3-glucoside to
healthy (pre)hypertensive men and women (40–80 year) produced a decrease of sE-selectin and IL-1β,
improving endothelial function [62].
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The endothelial dysfunction evaluated by reactive hyperemia improved in smokers was reduced
by administration of 400 mL green tea [63]. Furthermore, daily consumption of 8 g of green tea inhibits
endothelial dysfunction evaluated by flow-mediated forearm dilatation in smokers [64,65].
3. Flavonoids and Hypercholesterolemia
Cholesterol is transported through the aqueous environment of bloodstream by four different
proteins: chylomicron (CM), very low-density lipoprotein (VLDL), low-density lipoprotein (LDL),
and high-density lipoprotein (HDL). Chylomicron is formed in the intestinal lymphatic system,
and carries out the transport of cholesterol and triacylglycerols (TG) from the intestine to adipose
tissue and to skeletal muscles [66]. VLDL, transporting newly synthesized TG and cholesterol from
the liver to adipose tissue and skeletal muscles, is formed in liver, whereas LDL, which represents the
principal cholesterol carrier in blood, and transport cholesterol to the tissues that need it, is formed
in plasma and derives from intermediate-density lipoprotein (IDL) which receives cholesteryl ester
(CE) from HDL [67]. HDL takes the excess cholesterol from peripheral tissue and carries it back
to the liver, so it is involved in preserving plasma cholesterol homeostasis [67]. Two proteins, i.e.,
cholesteryl ester transport protein (CETP) and lecithincholesterol acyltransferase (LCAT), are involved
in regulating levels of circulating lipoprotein-cholesterol complexes (LDL-c and HDL-c). A further
role is played by two receptors, LDL receptor (LDL-R) and scavenger receptor B class 1 (SR-B1) [68].
Lecithin cholesterol acyltransferase is a 416 residues glycoprotein, mainly formed in liver and secreted
into plasma where it circulates in association with HDL. The enzyme catalyzes the transfer of the
sn-2 fatty acid of lecithin to the free 3-OH group of cholesterol, producing cholesteryl ester and
lysolecithin. The main substrate for LCAT is represented by HDL-cholesterol: LCAT plays a central
role in the maturation of HDL, and is involved in the determination of HDL composition, structure,
intravascular metabolism, and plasma concentration [69]. Low levels of LCAT are associated with
low levels of HDL-c [70]. CTEP (cholesteryl ester transfer protein) is involved in lipid metabolism:
it aids the exchange of lipids between lipoproteins through the transfer of cholesteryl esters from
HDL to LDL or VLDL, lowering HDL levels [71]. LDL receptors are membrane proteins carried to the
plasma membrane via the endoplasmic reticulum-Golgi pathway and then taken up via endocytosis
followed by recycling or degradation [72]. These receptors bind LDL particles and apolipoprotein B
(Apo-B) that are present in the extracellular fluid. The resulting receptor–ligand complex, which is
internalized through endocytosis via clathrin-coated pits through interactions involving the LDL
receptor adaptor protein, LDLRAP1 (also known as ARH), is carried by early endosomes to the
late endosomal compartment, where the acidic environment determines the dissociation of the
receptor-ligand complex: while the receptor is recycled to the cell surface, the LDL particles are
degraded by lysosomes. High free cholesterol content deriving from hydrolysis of cholesteryl esters
present in LDL core, leads to the inactivation of the Sterol Regulatory Element Binding Protein
2 (SREBP-2), which regulates the expression of genes for enzymes that determine the cholesterol
synthesis and the LDL receptor [73,74]. While LDL receptor is responsible for the removal of LDL-C
from circulation, the HDL receptor SR-B1 exerts the transport of HDL CE to the liver and steroidogenic
organs. The upregulation of SR-B1 receptors expression results in a lowering effect versus circulating
HDL [75]. Three transcriptional factors contribute to the control of cholesterol metabolism: sterol
regulatory element binding protein-2 (SREBP-2), liver X receptor (LXR), and farnesoid X receptor
(FXR) [76]. SREBP-2 controls the transcription for LDL receptors, and 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) reductase; LXR is involved in regulation of the transcription CYP7A1 encoding cholesterol
7R-hydroxylase, and plays a central role in bile acid synthesis; FXR is a bile acid receptor involved in
regulation of bile acid synthesis.
Finally, there are the acyl CoA: cholesterol acyltransferases ACAT-1 and ACAT-2, which catalyse
the intracellular esterification of cholesterol. ACAT-2 is required for cholesterol absorption in small
intestine, before cholesterol incorporation into CM. The same enzyme in liver has a central role in VLDL
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formation [76,77]. ACAT inhibition lowers plasma cholesterol level through inhibition of cholesterol
absorption in intestine and of VLDL production in the liver.
3.1. Flavonoids and Hypercholesterolemia: Effects on HMGCoA Reductase and LDL Receptors Expression
Oral administration of the quercetin glycoside rutin to streptozotocin-induced diabetic rats has
been shown to be able to reduce the levels of lipids in plasma and tissues. In particular, it was observed
that rutin increases plasma HDL cholesterol and decreases LDL and VLDL cholesterol: these events
are, in part, due to an observed reduction in activity of 3-hydroxy 3-methylglutaryl coenzyme A
(HMGCoA) reductase, and to the incease of plasma LPL and LCAT activities [78]. In accordance with
these results, administration of Scutellaria baicalensis stem-leaf total flavonoid to hyperlipidemic rats,
reduces total cholesterol, triglycerides, LDL-C, Apo-B concentration and increases HDL-c; partially
due to the observed increased activity of LCAT [79].
Isoflavones, flavones, and flavanones reduce blood cholesterol levels through inhibition of
cholesterol synthesis and increase of LDL receptor expression [79,80]. Soya isoflavones also affect
plasma cholesterol levels [81] through stimulation of the LDL receptor. Dietary isoflavones, such as
genistein or daidzein, induce a decrease in plasma cholesterol in C57BL/6 mice but not in LDL
receptor-deficient mice [82]. Isoflavonoids such as formononetin, biochanin A, and daidzein increase
LDL receptor activity in HepG2 cells [83]. This biological action is probably due to the effect of
flavonoids on SREBP-2 [84–95].
Two isoflavones isolated from bergamot (Citrus bergamia) juice, brutieridin and melitidin [84],
as well as kaempferol, naringenin, myricetin and EGCG [85] inhibit HMGCoA reductase activity. EGCG
competitively binds to the cofactor site of the reductase due to the steric hindrance to both NADPH
and HMGCoA binding. Green tea catechins reduce plasma cholesterol in different animal models and
influence favourably cholesterol metabolism in cell cultures [96], via the upregulation of LDL receptors
occurring through SREBP-2 activation at least in part due (−)-epigallocatechin-gallate (EGCG) [97–100].
Feeding rats a diet with 2% of green tea catechins results in a significant increase in LDL receptor
binding activity [101]. The same effect was observed in rabbits fed a hypercholesterolemic diet, treated
with a Green Tea Extract (GTE) [102]. The hypocholesterolemic activity of GTE is associated to the an
increased faecal bile acid and cholesterol excretion: in fact GTE administration to hamsters fed a 0.1%
cholesterol diet determines a decrease of total cholesterol and triglycerides and an increase in excretion
of both neutral and acidic sterols [93]. An analogue effect occurred in rats fed tea extracts [103–108].
3.2. Flavonoids and Hypercholesterolemia: Effects on ACAT Proteins
Several flavonoids, such as hesperidin, hesperetin, naringin, and naringenin, improve cholesterol
metabolism in vivo [97,98]. Naringenin and hesperetin inhibit the accumulation of Apo-B in HepG2
cells, in a concentration-dependent manner. This effect is achieved through inhibition of ACAT-1 and
ACAT-2 activities, a selective decrease in ACAT-2 expression, and an inhibition of MTP (microsomal
triglyceride transfer protein) activity which results in a lower availability of lipids, in particular
CE, essential for Apo-B-containing lipoproteins formation. The increased LDL receptor activity,
may be related to the estrogenic activity of these flavonoids, which is involved in the reduction of
Apo-B accumulation. In association with these biological events, inhibition of hepatic HMGCoA
reductase and ACAT activities and an increase in the faecal acidic sterols have been observed [100].
The administration of hesperetin or hesperetin metabolites, 3,4-dihydroxyphenylpropionic acid (DHPP)
(0.012%) and 3-methoxy-4-hydroxycinnamic acid (ferulic acid) (0.013%) to hypercholesterolemic
hamsters, , for 12 weeks, results in a significant decrease of plasma total cholesterol, non-high-density
lipoprotein-cholesterol (HDL-c), Apo-B, hepatic lipids, and cholesterol regulating enzymes, compared
to the control. Ferulic acid has been shown to be more potent in raising HDL-c/total cholesterol
ratio [101].
Two flavonoids extracted from Psoralea corylifolia, named bavachin and isobavacalchone, and
an isoprenyl flavonoid extract from licorice (Glycyrrhiza glabra) roots, glabrol, have been shown to
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inhibit ACAT activity in a concentration-dependent manner and in a non-competitive mode, and thus
affect cholesteryl ester formation in human HepG2 cells [109,110]. Naringin and naringenin exert
their hypocholesterolemic effect in high cholesterol diet fed rats, in part, through a slight inhibition of
hepatic ACAT, even if other mechanisms, such as HMG-CoA reductase inhibition, may be involved.
The effects of rutin and its metabolite, quercetin, on cholesterol metabolism have also been
investigated: oral administration of rutin to rats fed a high cholesterol diet results in a decrease in
serum level of total and LDL cholesterol and in a decrease of liver enzymes and weight [99]. According
to this data, it has been reported [111] that oral administration of rutin to streptozotocin-induced
diabetic rats increases HDL cholesterol and reduces levels of LDL- and VLDL-cholesterol, together
with the induced decrease of HMGCoA activity and the increase of plasma LPL and LCAT. Since oral
administration of rutin to normal rats does not alter these parameters, its beneficial effects may be due
to its antioxidant activities.
3.3. Flavonoids and Cholesterol: Clinical Studies
Consumption of soy phytoestrogens results in a decrease of plasma total and LDL- cholesterol
in hypercholesterolemic subjects [86,95]. Some authors reported that soy proteins with a high
isoflavone content consumption by normocholesterolemic subjects results in a great reduction of
LDL-c, in comparison with the same soy intake with a low isoflavone intake [82,83]. Conflicting data
have been obtained in two clinical trials where a high isoflavone diet gave the same results, in terms
of blood cholesterol, of a low-isoflavone diet [86–92]. Metanalysis showed that consumption of soy
protein with a high isoflavone content results in a stronger hypocholesterolemic activity than the same
diet with a low isoflavone content [93]. In another metanalysis [94], which included 23 randomized
control trials, it was observed that an isoflavone-rich diet results a great decrease in plasma total
cholesterol, LDL-c, triglycerides and a concommittant increase in HDL-c, while tablets based on
extracted isoflavones showed no effect on these parameters [95].
Furthermore, the administration of bergamot (C. bergamia Risso & Poiteau) fruits extract rich in
neoeriocitrin, naringin, neohesperidin, melitidin and brutieridin, for 30 days, to patients suffering
from hypercholesterolemia, resulted in a dose-dependent reduction of total and LDL cholesterol levels,
of triglyceride levels and an increase of HDL-c [106].
In addition, antocyanins may be clinically relevant, as supplementation with delphinidin-rich
maqui berry extract Delphinol®, at the daily dose of 180 mg, to prediabetic individuals, for 3 months,
resulted in a decrease of LDL-c [107].
Epidemiological data show a negative correlation between tea consumption and plasma levels
of total cholesterol and triglycerides in Japanese and Norwegian people. A theaflavin-rich tea
extract (375 mg/day) significantly decreases total cholesterol and triglycerides in subjects with mild
to moderate hypercholesterolemia [103]. However some conflicting results have been obtained:
a cross-sectional study showed no effect of green tea consumption toward lipid levels [104]. This result
is likely due to the daily low dose of catechins administered in the study; in fact the administration of a
Green Tea Extract (GTE) to postmenopausal women, at the daily dose of 5260 mg of catechins (1932 mg
of EGCG), for 12 months, produced a decrease of circulating TC and LDL-cholesterol concentrations,
in particular in those with elevated baseline TC concentrations [108].
4. Flavonoids and Diabetes: A Snapshot
A direct relationship between hyperglycaemia level and cardiovascular disease morbidity
and mortality has been demonstrated. In fact, patients suffering from diabetes and CVD show
coronary artery disease, peripheral vascular disease, cerebrovascular disease, diabetic cardiomyopathy,
and hypertensive cardiomyopathy [112–119]. This disease represents an increasing public health
problem in many countries [120]. Two types of diabetes are discerned: type 1, or insulin-dependent
diabetes, where body cannot produce insulin, generally occurs in children and young adults; type 2,
noninsulin-dependent, diabetes mellitus, characterized by fasting and postprandial hyperglycaemia
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and relative insulin insufficiency [120]. In recent years particular attention has been given to the
research of hypoglycaemic agents from natural products, in particular from those derived from plants.
Many studies reveal the potential role of flavonoids in the treatment of diabetes and indicate the
hypoglycaemic actions of flavonoids in different experimental models and treatments [121–125].
Epigallocatechin gallate, given intraperitoneally to rats, determines a reduction of blood glucose
and insulin levels [126–128]. The data demonstrate that green tea improves glucose metabolism in
healthy humans in oral glucose tolerance tests, and produces an anti-hyperglycaemic effect without
affecting insulin secretion in streptozotocin-induced diabetic mice [122]. Also genistein reduces
blood glucose levels in diabetic rats, compared with the control, in glucose tolerance tests. Similar
data have been obtained with chronic treatments with genistein and daidzein in db/db mice and
streptozotocin-induced rats [126–128].
Some flavonols, such as kaempferol, myricetin, rutin and its metabolite quercetin, show
hypoglycemic activity [129–131]. In particular, oral administration of rutin to diabetic rats results
in a plasma glucose levels reduction [130]. Different studies show that some flavonoids compete
with glucose in several absorption mechanisms indicating that intestinal absorption reduction may
represent one hypoglycemic effect. In fact, this action was observed into intestinal brush border
membrane vesicles of rabbits with a soybean extract which contains the two isoflavones genistein and
daidzein [131].
4.1. Flavonoids and Diabetes: Effects on α-glucosidase
Another way leading to a reduction of glucose absorption is represented by α-glucosidase
inhibition. As regards this biological activity, the two anthocyanins cyanidin-3-α-O-rhamnoside
and pelargonidin-3-α-O-rhamnoside reduce glucose absorption and inhibit α-glucosidase activity
in vitro [132]. The latter action was observed also with luteolin, kaempferol, chrysin and
galangin [133]. Luteolin-7-glucoside, luteolin, amentoflavone and daidzein are the strongest inhibitors
of α-glucosidase [134].
4.2. Flavonoids and Diabetes: Effects on Kidney Function
To better understand how flavonoids exert their hypoglycaemic activity, their influence towards
renal filtration system has been investigated. In particular, a sodium-coupled glucose transporters
found on the luminal membrane of the proximal tubule of the kidney, is responsible for the reabsorption
of glucose from renal filtrate. Precisely, the presence of glucose in urine is often found in diabetic
patients and can lead to severe renal impairment. Different works reported that some flavonoids may
interfere with renal glucose reabsorption process. Green tea flavonoids reduce the urinary excretion of
proteins and the renal morphological alterations related to diabetic nephropathy and ameliorate blood
glucose and glycosylated protein levels [135,136]. Puerarin, another flavonoid, is able to antagonize
the increase of collagen IV content in glomerular mesangial cells, so may contribute to the reduction of
the aggravating the occurrence and development of diabetic nephropathy [137].
4.3. Flavonoids and Diabetes: Effects on Pancreas and Insulin Secretion
Insulin exerts a central role in regulating blood glucose. Triggered by glucose, this hormone is
secreted into blood circulation by the β-cells of the endocrine portion of pancreas. Glucose enters
these cells via a protein named glucose transporter type 2 (GLUT-2). Once inside the cell, glucose
gets phosphorylated by glucokinase, the first step of glycolysis, which eventually leads to an increase
of ATP, which, binding to ATP-dependent-K+-channels, determines the closure of these channels,
which in turn causes cells depolarization. This event provokes the activation of voltage-sensitive
calcium channels, triggering a calcium influx, followed by insulin secretion [138]. Flavonoids may
influence the synthesis and the release of insulin from β-cells. In streptozotocin-diabetic rats, oral
administration of genistein has been shown to incease insulin secretion from mouse pancreatic islets,
in presence of glucose [139]. The mechanism underlying this biological effect may involve a rise in
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intracellular cAMP through the increase of adenylate cyclase activity and the activation of protein
kinase A (PKA), which suggests that genistein regulates the insulinotropic action through the activation
of the cAMP/PKA signalling cascade [140]. In addition, green tea catechins exert a hypoglycemic
activity in vitro and in vivo. In fact, chronic administration of a green tea-based supplement results in
an increase of the basal and insulin-stimulated glucose uptake in adipocytes [141,142].
Several in vitro studies show the protective effects of anthocyanins towards pancreatic
β-cells [143,144]. Chinese bayberry anthocyanins exert a protective activity towards pancreatic β-cells
INS-1 against induced necrosis and apoptosis, through ERK1/2- and PI3K/Akt-mediated heme
oxygenase-1 upregulation.
Anthocyanins and anthocyanidins induce insulin secretion from β-cells. In particular,
cyanidin-3-glucoside is less potent than delphinidin-3-glucoside at a lower glucose concentration,
while it is more potent at a higher glucose concentration; pelargonidin-3-galactoside does not affect
insulin secretion, while cyanidin-3-galactoside does, in the same conditions. These data suggest that
the number of hydroxyl groups in ring B of anthocyanins is relevant for their ability to induce insulin
secretion [144,145].
Cyanidin-3-glucoside (C3G), and cyanidin-3-rutinoside (C3R) induce insulin secretion in MIN
6 cells, through the upregulation of glucokinase and the activation of the GLP-1 receptor, triggering
the intracellular ATP accumulation, and favour β-cells survival through the improved expression
of duodenal homeobox factor-1 (PDX-1) [145]. Formononetin exerts antidiabetic effects through
several mechanisms including the inhibition of islet B cell apoptosis and the induction of islet B cell
regeneration down-regulating the Fas and Caspase-3 mRNA and protein levels and up-regulating
the PDX-1 and insulin receptor substrate 2 (IRS2) mRNA. Furthermore, it induces insulin secretion,
and up-regulates the GK and GLUT2 mRNA and protein levels in pancreas tissue from mice with
alloxan-induced type 1 diabetes [146] (Quercetin also stimulates insulin release, but with a different
mechanism, involving transient KATP channel inhibition and ICa stimulation [147]).
4.4. Flavonoids and Diabetes: Clinical Studies
A clinical study indicates that oral administration of silymarin results in a reduction of glycosuria
and glycaemia, even after four months of treatment [135].
In a randomized, placebo-controlled, double-blind trial, it has been demonstrated that daily
administration of 320 mg of anthocyanins, for 24 weeks, to diabetic patients, lowers fasting plasma
glucose, and decreases serum levels of LDL cholesterol and triglycerides [148]. One-year treatment with
genistein, at a daily dose of 54 mg, of Caucasian postmenopausal women with metabolic syndrome,
resulted in a decrease of fasting glucose, fasting insulin, and insulin resistance, total cholesterol,
LDL-C, triglycerides, visfatin, homocysteine and an increase of HDL-c and adiponectin [149].
Furthermore, the administration of 27 g/day (split dose) flavonoid-enriched chocolate (containing 850
mg flavan-3-ols [90 mg epicatechin] and 100 mg isoflavones) to patients with type 2 diabetes, for one
year, reduced peripheral insulin resistance, improved insulin sensitivity, and led to a decrease in total
cholesterol to HDL-c ratio, and a dcrease in LDL-c [150].
5. Conclusions and Perspectives
Atherosclerosis is considered one of the main medical and social problems in the industrialised
world, as it is strongly related to a plethora of chronic pathologies associated to an increase of morbidity
and mortality. Atherosclerosis has a multifactorial etiology, and it is associated to degenerative changes
in the wall of large arteries, inhibiting or suppressing blood flow to organs and tissues. The excessive
accumulation of lipids in the arterial intima represents a key step of the atherosclerotic process. Also,
oxidative stress and inflammation contribute to the onset and progression of atherosclerosis. At present,
there are no direct anti-atherosclerotic drugs, and the main strategy to prevent this pathology is
advice for a healthy lifestyle and, where necessary, prescription of antiperlipidemic, antidiabetic and
antihypertensive drugs.
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In this work we aim to focused on naturally occurring flavonoids able to act as multitarget
compounds, affecting several molecular networks activities and potentially providing preventive
and curative effects in patients with atherosclerosis, or at high risk of atherosclerosis. We recently
demonstrated the importance of kaempferol [151] and of kerala powder [152] and how the food tend
to influence the wellbeing. However, still a lot of efforts are necessary to better explore the many
pathways of both cardiovascular diseases and diabetes.
Flavonoids may be relevant in the prevention and treatment of atherosclerosis and
atherosclerosis-related disorders as they act as antioxidant, hypocholesterolemic and antidiabetic
agents. Therefore, is promising to investigate different flavonoids metabolites that could help to
prevent and/or manage certain type of disorders. The great potential of these compounds should
goad to probe deeply the molecular mechanisms involved.
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